Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate

Basit Öğe Kaydı
dc.authorid0000-0003-1919-3183
dc.authorid0000-0002-4607-5724
dc.authorid0000-0001-9975-5507
dc.authorid0000-0002-4281-0867
dc.authorid0000-0002-7322-5070
dc.contributor.authorKızılırmak, Filiz
dc.contributor.authorGüneş, Hacı Murat
dc.contributor.authorGüler, Ekrem
dc.contributor.authorDemir, Gültekin Günhan
dc.contributor.authorKaraca, Oğuz
dc.contributor.authorCanpolat, Habibe Gamze
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:01:37Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:01:37Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.descriptionWOS: 000368568400013
dc.descriptionPubMed ID: 26798391
dc.description.abstractDabigatran etexilate is one of the new oral anticoagulants approved to reduce the risk of stroke in patients with atrial fibrillation (AF). A variety of bleeding complications with dabigatran have been reported, but reports of hemopericardium are rare. We described a case of a 66 year-old female patient with non-valvular AF receiving dabigatran etexilate 150 mg twice daily for one year who suffered from hemopericardium. Her laboratory tests performed 1 year prior were normal and her admission tests revealed acute renal failure and elevated international normalized ratio (INR) level (4.79). Urgent pericardiocentesis was followed by improved renal functions and normalized INR. Dabigatran etexilate is a new oral anticoagulant that is increasingly used in daily practice. However, life-threatening complications warrant caution. Elevated INR may be related with overdose but the association of bleeding risk of dabigatran and INR requires further confirmation.
dc.identifier.citationKızılırmak, F., Güneş, H. M., Güler, E., Demir, G. G., Karaca, O. ve Canpolat, H. G. (2016). Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate. Korean Circulation Journal, 46(1), 99-101. https://dx.doi.org/10.4070/kcj.2016.46.1.99
dc.identifier.doi10.4070/kcj.2016.46.1.99
dc.identifier.endpage101
dc.identifier.issn1738-5520
dc.identifier.issn1738-5555
dc.identifier.issue1
dc.identifier.scopusqualityQ2
dc.identifier.startpage99
dc.identifier.urihttps://dx.doi.org/10.4070/kcj.2016.46.1.99
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3367
dc.identifier.volume46
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKorean Soc Cardiology
dc.relation.ispartofKorean Circulation Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPericardial Effusion
dc.subjectDabigatran Etexilate
dc.subjectAtrial Fibrillation
dc.titleHemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kizilirmak-Filiz 2016.pdf
Boyut:
163.35 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu